Screener
Xenon Pharmaceuticals XENE Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 13,553 | 10,392 |
| Total current assets | 945,868 | 560,649 |
| Marketable securities, long-term (note 5) | 314,411 | 37,152 |
| Operating lease right-of-use asset, net (note 6) | 5,385 | 6,626 |
| Property, plant and equipment, net | 7,774 | 8,721 |
| Deferred tax assets | 14,361 | 12,864 |
| Prepaid expenses, long-term | 7,973 | 7,151 |
| Total assets | $1,295,772 | $633,163 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's operating lease ROU assets?
- Xenon Pharmaceuticals (XENE) reported operating lease ROU assets of $5.39M in Q2 2026.
- How has Xenon Pharmaceuticals's operating lease ROU assets changed year-over-year?
- Xenon Pharmaceuticals's operating lease ROU assets decreased by 26.1% year-over-year, from $7.29M to $5.39M.
- What is the long-term trend for Xenon Pharmaceuticals's operating lease ROU assets?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's operating lease ROU assets has grown at a 14.8% compound annual growth rate (CAGR), from $3.33M to $6.63M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Xenon Pharmaceuticals's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude